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Chagas disease is caused by Trypanosoma cruzi and affects thousands of people. Drugs currently 
used in therapy are toxic and have therapeutic limitations. In addition, the genetic diversity of T. 
cruzi represents an important variable and challenge in treatment. Sodium diethyldithiocarbamate 
(DETC) is a compound with pharmacological versatility acting as metal chelators and ROS generation. 
Thus, the objective was to characterize the antiparasitic action of DETC against different strains and 
forms of T. cruzi and their mechanism. The different strains of T. cruzi were grown in LIT medium. To 
evaluate the antiparasitic activity of DETC, epimastigote and trypomastigote forms of T. cruzi were 
used by resazurin reduction methods and by counting. Different response patterns were obtained 
between the strains and an  IC50 of DETC ranging from 9.44 ± 3,181 to 60.49 ± 7.62 µM. Cell cytotoxicity 
against 3T3 and RAW cell lines and evaluated by MTT, demonstrated that DETC in high concentration 
(2222.00 µM) presents low toxicity. Yet, DETC causes mitochondrial damage in T. cruzi, as well as 
disruption in parasite membrane. DETC has antiparasitic activity against different genotypes and 
forms of T. cruzi, therefore, representing a promising molecule as a drug for the treatment of Chagas 
disease.
Chagas Disease (CD) is a Neglected Tropical Disease (NTD) caused by flagellated protozoan Trypanosoma 
cruzi. This disease affects more than 8 million people worldwide, causing more than 10,000 deaths per year and 
has more than 80 million people living in risk  zone1. CD presents an acute asymptomatic phase or nonspecific 
clinical signs, and a chronic phase, individuals may be asymptomatic or progress to cardiac and/ or digestive 
 complications2. CD can be transmitted in different ways and the two main transmission mechanisms are vector 
transmission, during blood meal of triatomines, and ingestion of food contaminated with faeces of these  vectors3. 
However, other transmission mechanisms also contribute to CD, such as blood transfusion, organ transplants, 
and vertical congenital transmission responsible for the dissemination of CD in other non-endemic  countries4.
T. cruzi is a flagellated protozoan that belongs to the trypanosomatid family. The parasite has a complex 
heteroxenic life cycle that maintains its biological cycle between the invertebrate host of the Triatominae family 
and the mammalian host (humans, dogs, and wild animals) passing by metacyclogenesis during this cycle, suf-
fering alteration in different  forms5. Although T. cruzi is represented by a single species, the diversity and genetic 
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variability of this parasite is made of different strains, grouped based on their genetic characteristics, named 
Discrete Typing Units (DTUs)6. Thus, T. cruzi can be classified into seven different genetic variants or genotypes, 
in which several strains were included, called from TcI to TcVI, and, more recently, the variant called  TcBat6,7. 
These genetic variants of T. cruzi are important from an epidemiological point of view, as they are involved in 
different aspects of CD, mainly in the context of the transmission cycle, clinical manifestations, pathogenesis, 
reservoir and geographical  distribution8.
In the context of pharmacological therapy for CD, the drugs currently used are benznidazole and  nifurtimox9. 
These two nitroaromatic-compounds act on the parasite by producing reactive oxygen species (ROS), thus pre-
senting antiparasitic activity. However, based on clinical point of view, these drugs have limitations regarding 
their use, since they are responsible for several adverse reactions like liver damage, pruritus, spots on the skin, and 
itchy in  eyes10. Additionally, these drugs have low pharmacological efficacy in the chronic phase of infection with 
T. cruzi11. This fact has led to the search for new compounds that may be more effective in the treatment of CD.
Diethyldithiocarbamate (DETC) is a compound that belongs to the class of dithiocarbamates, formed by two 
ethyl substituents linked to an amine group, which in turn is linked to carbon disulfide. The chemical structure 
of DETC has two distinct portions; the first, an amine portion formed by nitrogen and the two ethyl groups that 
stimulate the production of reactive oxygen species. The second portion, a carbon disulfide end that can chelate 
on metals, thus attributing an essential biological activity of this compound against metalloproteases, enzymes 
necessary for parasitic  biology12–14. Due to the structural characteristics of DETC, several pharmacological 
applications were observed in this  compound15–21. In addition, we recently published a review that addresses 
the different justifications for enhancing DETC as a potential antiparasitic  drug15.
However, little is known about the antiparasitic activity of DETC against T. cruzi. Thus, the aim of this study 
is to evaluate the antiparasitic activity of DETC in vitro against the different strains (different DTUs) and forms 
of T. cruzi. Therefore, in this work we report, for the first time, the antiparasitic activity of DETC against different 
strains of T. cruzi, as well as insights into its mechanisms of action as an antiparasitic drug.
Results
DETC in vitro antiparasitic activity towards T. cruzi. The count of viable parasites by optical micros-
copy after treatment with DETC in different concentrations is presented in Fig. 1. Based on these results, it is 
possible to analyse that DETC causes a elevate toxicity against parasite depending of time of exposure and con-
Figure 1.  Evaluation of resazurin reduction inhibition by different strains and forms of Trypanosoma 
cruzi treated with DETC. Parasitic inhibition of resazurin reduction (%) of DETC against different forms 
(epimastigotes and trypomastigotes) and strains (Y, Dm28c, CL Brener, and QMM9) of T. cruzi, after 24 and 
48 h of culture and analysed by resazurin assay. (A) Epimastigotes for 24 h of treatment; (B) Trypomastigotes 
for 24 h of treatment; (C) Epimastigotes for 48 h of treatment; (D) Trypomastigotes for 48 h of treatment. 
Results presented as mean ± standard deviation of the percentage of parasitic inhibition in a triplicate system 
and for the statistical analysis of the Anova Test, together with the Tukey Post-test (P < 0.01 (**); P < 0.001 (***), 
P < 0.0001(****). In order to verify differences, the profile of each strain was compared against others treated 
with the same concentration of DETC. Software GraphPad Prism v. 7.0 (2016) (https:// www. graph pad. com/).
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centration applied. In addition, the effect of DETC is variable according with parasite form, in which epimastig-
ote forms were most susceptible than trypomastigote forms.
QMM9 and CL Brener strains of T. cruzi demonstrated to be more susceptible than Dm28c and Y strains in 
low concentrations of DETC in the epimastigote form after 24 h of exposure. However, the increase of DETC 
concentration ended up affecting almost equally Dm28c, Y and Cl Brener strains, though the QMM9 strain was 
less affected in high concentrations of DETC. When epimastigote forms of T. cruzi were exposed 48 h at DETC, 
it was observed an accumulation of damage suffered by parasite. Even so, the QMM9 strain have been showed 
more resistance against DETC, but in higher concentration all strains do not present viable parasites.
The trypomastigote forms of parasite present a similar profile at epimastigote forms, but the Dm28c strain 
demonstrated a higher susceptibility at DETC than other strains. Furthermore, the trypomastigote forms present 
a higher resistance against DETC when compared with results achieved in epimastigote forms of T. cruzi. To 
confirm the antiparasitic activity of DETC against T. cruzi, the viability of parasites treated with DETC was also 
determined by resazurin metabolization. These results are shown in Fig. 1S. When comparing results presented 
in Fig. 1 with data in Fig. 1S, the same profile of DETC antiparasitic activity against T. cruzi is observed in both 
assays.
The  IC50 of DETC was determined based on counting of viable parasites and values are shown in Table 1 and 
the results based on resazurin reduction are shown in Table 1S. The  IC50 of DETC towards each strain of T. cruzi 
was different in the conditions tested, and the trypomastigote profile presented a higher  IC50, when compared 
with epimastigote, except for QMM9 strain. When compared with  IC50 of benznidazole and tested in the same 
conditions of DETC, the  IC50 of benznidazole was always higher for all strains in both forms.
The QMM9 strain was less affected by exposure to DETC, it showed the highest  IC50 among the tested strains. 
Meanwhile, with the smallest  IC50, the Dm28c strain was the most affected by exposure to DETC. The Y and CL 
Brener strains have similar profiles in epimastigotes, and different responses in trypomastigotes. Furthermore, 
the Y, QMM9 and CL Brener strains have a lower  IC50 in trypomastigote form when compared with the result 
in epimastigote form. At the same time, QMM9 strain had a reduced in  IC50 of epimastigote form compared 
with the trypomastigote form.
In addition, the correlation between each  IC50 result of DETC and benznidazole against all strains in different 
forms was also determined. Based on the results obtained, a R square > 0.88 to all strains tested was observed 
through the Pearson Correlation, representing a strong correlation between results of DETC and benznidazole. 
The effectiveness of the anti-parasitic activity of DETC was also compared with the effectiveness of benznidazole 
for each strain and evolutionary form evaluated in this study.
Additionally, in order to validate the effectiveness of the DETC antiparasitic activity against T. cruzi strains, 
the parasites treated with DETC and with 100% resazurin reduction capacity were re-cultivated in a new culture 
medium, and after 7 days of culture these parasites had no cell viability (results not shown).
Visualization of DETC damage towards Trypanosoma cruzi. In order to observe if the exposure to 
DETC by different strains of T. cruzi causes morphological changes in the parasite membrane structure after 
treatment, the parasites had their membrane structure analysed by scanning electron microscopy (SEM). Fig-
ure 2 has four columns; the first column shows the images 1, 5, 9, and 13 corresponding to the control of Y, 
Dm28c, QMM9 and CL Brener strains, respectively. These images show the normal morphology of the parasite 
without treatment with DETC. The remaining images present in the second, third and fourth columns show the 
parasites treated with DETC. Three images of each strain treated with DETC were used to visualize the damage 
suffered by T. cruzi treated with DETC. Based on the images it was possible to observe different alterations suf-
fered by the parasite. In the Y strain of T. cruzi (images 2, 3, and 4) we observed pores in the membrane in large 
scale. In the Dm28c strain of T. cruzi (images 6, 7, and 8) we observed a large damage in the parasite membrane 
and the presence of pores, but they are fewer than in the Y strain of T. cruzi. In the QMM9 strain of T. cruzi 
(images 10, 11, and 12) we observed alterations in the membrane morphology, lacks in the membrane, disrup-
tions and small pores. Finally, in the CL Brener strain of T. cruzi (images 14, 15, and 16) we observed big pores 
and alterations in the parasite membrane morphology.
EDS analysis was used as a quality control for the structures shown in the SEM images (Fig. 2S). The car-
bon structure of the parasites inserted in the correct place on the silicon plate and low salt concentration were 
observed in the samples used in the SEM analysis. For the images used in the SEM analysis, an EDS analysis was 
performed to verify and confirm the results obtained.
Table 1.  DETC antiparasitic activity, expressed in  IC50 values ± standard deviation, against the different strains 
and forms of Trypanosoma cruzi after 24 h of exposure, based on results expressed by couting essay. The 
statistical analysis the Anova Test together with the Tukey Post-test. The statistical analysis used measure the 
 IC50 value in each group under same conditions. BZN benznidazole.
Trypanosoma cruzi strains (DTUs)
IC50 epimastigote IC50 trypomastigote
DETC (μM) BZN (μM) DETC (μM) BZN (μM)
Strain Dm28c (TcI) 37.13 ± 7.58a 78.12 ± 8.01a 40.12 ± 6.58a 91.95 ± 2.87b
Strain Y (TcII) 50.41 ± 3.56b 96.66 ± 5.38b 31.19 ± 7.21b 98.74 ± 3.98b
Strain QMM9 (TcIII) 60.15 ± 6.45b 101.38 ± 5.39b 46.76 ± 5.11a 103.47 ± 2.45c
Strain CL Brener (TcVI) 49.12 ± 5.78b 71.56 ± 7.98a 43.83 ± 4.55a 82.43 ± 5.83a
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DETC cytotoxicity in vitro cell culture. The next step was to assess the DETC effect on the ability of 
mammalian cells to reduce MTT. Therefore, RAW and 3T3 cell lines were submitted to DETC (from 4.44 to 
2222.0 µM) for 24 h, as described in the methods section. As shown in Fig. 3, DETC affected the cells’ ability to 
reduce MTT. Low concentrations of DETC affected RAW more than 3T3 cell lines. From the concentration of 
11.1 µM to 111.0 µM, the RAW cells was more sensitive, statically observed from concentration 222.0 µM, RAW 
and 3T3 cell lines had similar profiles of response against DETC. In this case, the ability of both cells to reduce 
MTT decreased to around 50%, and did not decrease, even with an increase in the concentration (from 1111.0 to 
2222.00 µM) of DETC. The  IC50 of each cell line was determinated based on the decrease of reduce MTT when 
exposed to DETC. Then, based on the MTT metabolization curve, present in Fig. 3, for each cell line, the  IC50 
values were calculated, 859.90 µM and 698.80 µM for cellular lineages, 3T3 and RAW, respectively.
The selectivity index (SI) was determined based on the data from the resazurin and the MTT assays, as 
described in the Methods section. Table 2 shows the different SI of DETC obtained with different strains in try-
pomastigote form of T. cruzi. In addition, the different strains associated with each cell line presented different SI. 
The selectivity of DETC for the QMM9 strain towards the cell lines 3T3 and RAW, presented the smaller values 
of SI for both forms and cellular lineages. Meanwhile, selectivity for the Y strain towards cell lines presented 
higher values of SI and cellular lineages. Furthermore, the SI of DETC for the CL Brener and QMM9 strains 
presented a similar profile.
Mechanisms of cellular death in Trypanosoma cruzi after treatment with DETC. Annexin V/PI 
assay, markers of cellular death, was analyzed towards different forms and strains of T. cruzi when treated with 
DETC. The profile of trypomastigote forms treated with DETC is shown in Fig. 4 and the epimastigote form in 
Fig. 3S. Based on these results it is possible to observe the absence of death cellular markers Annexin V/PI in all 
Figure 2.  Morphological changes of Trypanosoma cruzi epimastigotes treated with diethyldithiocarbamate and 
analysed by scanning electron microscopy. Image 1 corresponding to the control of strain y, 2—4 corresponding 
to the treatment with DETC in concentrations 44 µM (2), 111 µM (3) and 222 µM (4); image 5 corresponding 
to the control of strain Dm28c, 6—8 corresponding to the treatment with DETC in concentrations 44 µM (6), 
111 µM (7) and 222 µM (8); images 9 corresponding to the control of strain QMM9, 10—12 corresponding 
to the treatment with DETC in concentrations 44 µM (10), 111 µM (11) and 222 µM (12); and image 13 
corresponding to the control of strain CL Brener corresponding to the treatment with DETC in concentrations 
44 µM (14), 111 µM (15) and 222 µM (16), 14—16 . The yellow arrows in the figure indicate the presence of pore 




Scientific Reports |        (2021) 11:11200  | https://doi.org/10.1038/s41598-021-90719-0
www.nature.com/scientificreports/
strains of T. cruzi, when exposed to different concentrations of DETC (4.44 µM, 44.40 µM, 444.00 µM). These 
concentrations were used based on results of resazurin and counting of parasites, seeking to identify the mecha-
nism of death related to the stain Annexin V/PI by flow cytometry.
Data for Y and Dm28c strains of T. cruzi when treated with DETC was similar to those observed with 
untreated parasites, that is, more 97% of parasites were considered viable, even when DETC was used at higher 
concentration (444.00 µM). However, a low fluorescence response of death cellular markers Annexin V/PI was 
verified to CL Brener and QMM9 strains of T. cruzi, when exposed to highest concentration of DETC. 71% and 
80% of viability was identified for both strains after exposure, respectively.
Mitochondrial damage in Trypanosoma cruzi after treatment with DETC. A second possible 
death cell mechanism was evaluated by the mitochondrial activity assay using rhodamine-123. In this case, the 
parasites were treated with different concentrations of DETC (44.4 µM; 111.0 µM; and 222.0 µM) and subse-
quently, the fluorescence rhodamine-123 stain was detected by flow cytometry. These concentrations were used 
to visualize the effect of DETC towards the parasite exposed for 24 h. The concentration of 444.0 µM DETC was 
not used to prevent the death of 100% of the parasites, and thus making the rhodamine-123 assay unfeasible.
The fluorescent profile of rhodamine-123 in each T. cruzi strain when exposed to DETC is shown in Fig. 5A. 
The results shown in Fig. 5A were quantified and used to produce Fig. 5B. All T. cruzi strains treated with DETC, 
when compared to the control, show a reduction in the fluorescence profile for rhodamine-123. The increase 
in DETC concentration affects the fluorescence intensity of the parasite for rhodamine-123 by flow cytometry. 
Y and QMM9 strains of T. cruzi were the least susceptible to DETC, with a similar profile of reduction in fluo-
rescence emission, and the Dm28c strain was the most susceptible to DETC, resulting in smaller fluorescence 
when compared with control.
Reactive oxygen species production in Trypanosoma cruzi after treatment with DETC. The 
reactive oxygen species (ROS) production in trypomastigote forms of T. cruzi after treatment with DETC for 
24 h are shown in Fig. 6. The results demonstrated, when compared with control all strains after treatment with 
DETC, an increase in reactive oxygen production. The Dm28c and Y strains were most affected after treatment 
with DETC when analysed the increase of ROS. However, the increase of concentration after 44.4 µM presented 





















Figure 3.  Evaluation of the MTT reduction in 3T3 and RAW cell lines exposed to diethyldithiocarbamate. 
Viability curves of the 3T3 and RAW cell lines obtained through the MTT reduction assay when treated 
with different concentrations of DETC for 24 h. 100% of MTT reduction represents cells untreated. The 
curves present in this image were constructed based on mean ± standard deviation of the percentage of MTT 
reduction for each cell line (RAW and 3T3). To compare the MTT metabolization of each cell lines against same 
concentration of DETC treatment, a statistical analysis was performed using T de student Test. The statistical 
analysis showed difference in metabolization on range concentrations from 11.1 to 44.4 µM P < 0.001 (***). 
Software GraphPad Prism v. 7.0 (2016) (https:// www. graph pad. com/).
Table 2.  Selectivity index (SI) of diethyldithiocarbamate in different strains in trypomastigote form of 
Trypanosoma cruzi after 24 h of cultivation Different forms of T. cruzi epimastigote (Epi) and trypomastigotes 
(Trypo) and cell lines (3T3 and RAW cells).
Trypanosoma cruzi strains (DTUs) 3T3: Trypo RAW: Trypo
Strain Dm28c (TcI) 34.396 27.952
Strain Y (TcII) 36.827 29.927
Strain Qmm9 (TcIII) 16.076 13.064
Strain CL Brener (TcVI) 19.914 16.183
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a reduction of ROS production when compared with previous concentration. The QMM9 and Cl Brener strains 
presented a similar profile of ROS production.
Discussion
This work evaluated the antiparasitic activity of DETC against four different strains of T. cruzi: Dm28c (TcI), Y 
(TcII), QMM9 (TcIII), and Cl Brener (TcVI) strains. The antiparasitic activity data of DETC (Fig. 1, Fig. 1S and 
Table 2) show that different strains of T. cruzi have different levels of susceptibility. Previously, dithiocarbamate 
was classified as a group compounds with high activity against T. cruzi. Studies have shown the antiparasitic 
activity of different compounds based on dithiocarbamates against T. cruzi, probably due to the inhibition of the 
enzyme Superoxide Dismutase enzyme (SOD) and other molecules of the oxidative pathway of the  parasite22,23. 
Furthermore, the different inhibitory resazurin profile and counting for different strains after treatment with 
DETC is in agreement with results obtained by others authors. They notice that different patterns of response 
Figure 4.  Analysis of the cell death mechanism of trypomastigotes from different Trypanosoma cruzi strains 
treated with DETC. The parasites death cell mechanism was evaluated by flow cytometry as to the capacity 
for Annexin/PI stain after 24 h of treatment with different DETC concentrations; 4.44 µM; 44.44 µM; and 
444.00 µM. Flow cytometer (FACSCanto II, BD Biosciences, Eugene, OR, USA) with FACSDiva software, 
version 6.1.2 (Becton Dickson, Franklin Lakes, NJ, USA) (https:// www. bdbio scien ces. com/ en- us/ instr uments/ 
resea rch- instr uments/ resea rch- softw are/ flow- cytom etry- acqui sition/ facsd iva- softw are).
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should be associated with phylogenetic and evolutionary processes that act making the strains resistant or sus-
ceptible at  compound24–26.
The experiments performed in this work, based on counting and resazurin reduction, used concentrations 
different of  IC50, adopting as pattern 44.4 µM, 111.0 µM, and 222.0 µM, except the annexinV/PI have been used 
4.44 µM, 44.4 µM and 444.00 µM to demonstrate that the concentration applied almost not change the result 
present, whether in high concentrations or lower concentrations. In the others experiments, the approach that 
we came here, is based in different profile observed in results between strains of T. cruzi. The use of different 
concentrations allowed observe and have a better interpretation of how the strains of parasite response under 
different concentrations of DETC and find better explanations.
In addition, a different profile of inhibition was demonstrated when the alteration in evolutionary form of 
T. cruzi occurs, in this case, the epimastigote and trypomastigote forms. The different profiles in evolutionary 
Figure 5.  Evaluation of the mechanism of mitochondrial damage caused by DETC in Trypanosoma cruzi. 
(A) Fluorescence intensity (rhodamine-123) in different strains in trypomastigote form of T. cruzi untreated 
(control), represents 100% of fluorescence, and treated with different concentrations of DETC (44.4 µM, 
111.0 µM, 222.0 µM) for 24 h. (1) Y strain; (2) Dm28c strain; (3) CL Brener strain; (4) Qmm9 strain. 10,000 
events were used for each analysis to obtain the data, which was carried out in triplicate. (B) Fluorescence 
intensity (%) of rhodamine-123 inhibition of different strains of T. cruzi treated with different concentrations of 
DETC. The results were presented based on mean ± standard deviation of the percentage of parasitic inhibition. 
The statistical analyses were performed using the Anova Test with the Tukey Post-test (P < 0.01 (**); P < 0.001 
(***). The statistical analyses were used to compare the profile of each strain treated with the same DETC 
concentration. Flow cytometer (FACSCanto II, BD Biosciences, Eugene, OR, USA) with FACSDiva software, 
version 6.1.2 (Becton Dickson, Franklin Lakes, NJ, USA) (https:// www. bdbio scien ces. com/ en- us/ instr uments/ 
resea rch- instr uments/ resea rch- softw are/ flow- cytom etry- acqui sition/ facsd iva- softw are) and software GraphPad 
Prism v. 7.0 (2016) (https:// www. graph pad. com/).
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forms towards treatment with DETC are associated with metacyclogenesis processes. In these processes, there is 
an alteration in protein expression, RNA and changes in the parasite structure, which acts directly or indirectly 
in the strain resistance at  compound27–29.
It is worth mentioning that QMM9 strain showed the more resistant profile in the DETC treatment and the 
same was observed when exposed to the conventional drug used in CD treatment (benznidazole)30. However, 
this strain was recently isolated and characterized, and therefore there are no studies with mechanisms or causes 
for this high resistance.
Our results show that DETC has a better antiparasitic activity against T. cruzi than benznidazole, when com-
pared in vitro and in the experimental conditions established in this study. In another study, it was observed that 
benznidazole presents an  IC50 < 10 μM against Y strain of T. cruzi31. However, here we used a higher concentration 
of parasites for antiparasitic assay  (107 parasites/mL). In the other study the antiparasitic activity was determined 
in a lower concentration of parasites  (106 parasites/mL). In addition, we analysed the antiparasitic activity of 
DETC and benznidazole in shorter exposure times (24 and 48 h), while many other authors use benznidazole 
treatment in 72  h31,32.
To evaluate the damage caused by DETC in parasite structure, SEM analysis was used after treatment with 
DETC for 24 h. It was observed that DETC causes severe damage in parasite structure and acts in pore forma-
tion (Fig. 2). In the literature, DETC was characterized as an inhibitor of antioxidative enzymes, causing the 
accumulation of reactive species inside cell or parasite. The excessive presence of reactive species causes a lot 
of damage and leads to the formation of pores. In others studies that used a compound able to trigger the same 
increase of reactive species, the formation of pores was in SEM analysis and membrane  damage33,34.
With regard to the DETC cytotoxic profile, in this study we observed the viability of the 3T3 and RAW cell 
lines treated with DETC for 24 h (Fig. 3). Only in high concentrations (1111.0 μM and 2222.0 μM), DETC was 
able to significantly reduce the viability of the 3T3 and RAW cell lines, but not less than 40% of cell viability. Even 
at high concentrations, DETC was not toxic enough to cause 100% mortality of the cell lines. However, even in 
low concentrations, DETC has 100% antiparasitic activity. With these data it was also possible to determine the 
selectivity index (SI) of DETC of different strains and forms of T. cruzi (Table 2). Based on the SI, DETC showed 
less toxicity for fibroblast cell lines when compared to benznidazole and  derivatives35. In addition, DETC has 
less toxicity than benznidazole when evaluated in RAW cell  lines36. These results corroborated the evaluation of 
in vitro DETC efficacy compared with conventional drugs used in treatment of CD.
In this work, we take an approach showing DETC as a potent inhibitor of T. cruzi activity. In others studies 
using DETC against parasites of Trypanosomatidae  family20,21, DETC showed an important Fe-SOD inhibitor 
resulting in  O-2 accumulation and causing the parasite to die. In vitro studies have also shown that DETC can 
inhibit Fe-SOD of T. cruzi22,23. Therefore, when analyzing the stain of Annexin V/PI (Fig. 4 and Fig. 3S), the 
absence or low staining for both evolutionary form and for different strains of parasite was observed. This result 
was expected, has it was observed that SOD inhibitors can blocked apoptosis pathway and denied the cascade 
signalization to expose phosphatidylserine in membrane, since the stain was not  detected37,38. Furthermore, 
studies with dithiocarbamates showed compound’s capacity to inhibit the apoptosis pathway and induce non-
specific  necrosis39.
The structure of DETC may act by producing reactive species and causing inhibition of antioxidative enzymes. 
Inside cells and parasites, the site most commonly associated with reactive species production and neutraliza-
tion is the mitochondria. Therefore, in our work we evaluate whether DETC could attack and damaged the 
mitochondria. When observing the results present in Fig. 1S and Fig. 5, both resazurin and rhodamine-123 are 
metabolized inside the mitochondria. It is known that the metabolism of these two compounds by the parasite 
is directly related to the functioning of complexes I, II and III of the inner membrane of the  mitochondria40. 
Figure 6.  Evaluation of reactive oxygen species production in trypomastigote forms of T. cruzi after 24 h of 
exposure at DETC. The different strains of T. cruzi were treated with 4 concentrations of DETC (22.2 µM, 
44.4 µM, 111.00 µM and 222.00 µM. Results presented as mean ± standard deviation of the percentage of 
parasitic inhibition in a triplicate system and for the statistical analysis the Anova Test together with the Tukey 
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The reduction phenomenon of the resazurin and rhodamine-123 compounds may be related to the damage of 
the mitochondrial inner membrane of T. cruzi due to the action of DETC. Consequently, causing a malfunc-
tion in the regulation of the protonation gradient carried out by the mitochondrial complexes I, II and III, and 
impairing ATP synthesis, and subsequently causing the death of the  parasites40–43. Interestingly, it can be seen in 
Fig. 5 that the highest concentration of DETC (222.0 µM) is able to reduce the metabolism of rhodamine-123 in 
all strains of T. cruzi analysed in this study, probably associated with the reduction of the membrane potential 
mitochondrial, potentiating the mitochondria as a possible target for the anti-T.cruzi activity presented by DETC.
T. cruzi treated with DETC shows damage and pore formation in the cytoplasmic membrane. This phenom-
enon can also be a consequence of mitochondrial damage induced by DETC. Some studies report the capacity of 
mitochondrial damage caused by the production of reactive species, a possible explanation for the antiparasitic 
mechanism presented by  DETC44–46.
When analysing the results present in Fig. 6 demonstrating the increase in ROS in T. cruzi according to the 
exposure at DETC in different concentrations. The different profiles present by parasites are in agreement with 
the results presented in others experiments. Strain Dm28c proved to be more susceptible in the trypomastigote 
(Fig. 1) form and suffered higher mitochondrial damage in low concentrations of DETC (Fig. 5), these results 
may be associated with a higher ROS production in lowers concentrations of DETC, observed in Fig. 6. The 
reduction of ROS production by all strains after treatment, observed in highest concentrations (111.00 µM and 
222.00 µM), is associated with high death of parasites after treatment with DETC in these concentrations (Fig. 1), 
due to the reduction of the ROS production level in these concentrations. Furthermore, the results presented 
in Fig. 6 corroborate with others results present in this work and reinforce the idea of the importance of ROS 
damage for the parasite elimination.
In addition, when observe the ROS production by parasite exposed at DETC in different concentrations, the 
increase of ROS present a similar profile than other classes of compounds tested against T. cruzi that present 
the same mechanism. Nevertheless, studies using benznidazole and derivatives present results with lower ROS 
production in 24 h when compare with results demonstrated in this work. Therefore, DETC present an inter-
esting result in ROS production against different strains of T. cruzi corroborating with other authors those use 
compounds with capacity of stimulate ROS  production55–57.
In conclusion, in this work we demonstrated the antiparasitic activity of DETC against different forms (epi-
mastigotes and trypomastigotes) and four different strains of T. cruzi, the etiological agent of CD. When we 
compared the antiparasitic activity of DETC with benznidazole, the first-line drug for the treatment of CD, 
DETC showed better antiparasitic activity in vitro. Finally, new assays and validations are necessary in order to 
enhance the use of DETC as a promising candidate in the treatment of Chagas disease.
Methods
Axenic cultivation of Trypanosoma cruzi. Different strains of T. cruzi TcI (strain Dm28c)47; TcII (strain 
Y)48; TcIII (QMM9 strain)30 and TcVI (CL Blener strain)49 were grown in LIT (Liver Infusion Tryptose) medium 
supplemented with 10% inactivated fetal bovine serum (FBS) (v/v) and 5% of antibiotic streptomycin/penicillin 
(100 UI/mL). All strains were donated by Laboratório de Parasitologia (FCFAr), Araraquara, Brazil. The epimas-
tigote forms of T. cruzi were kept at 27 ºC in a BOD oven (incubator chamber, ASP, SP-500). The trypomastigote 
forms of T. cruzi were obtained through the nutritional stress method, from the epimastigote forms of the para-
site for a period of 25 days, according to the methodology developed by Camargo et al.,  196450. Briefly, 20 mL of 
cell culture were kept in 50 mL flasks. The flasks were kept closed and the parasites were subsequently analysed 
for cell viability and differentiation morphological changes. The morphological changes of the parasites were 
analysed by optical microscopy, and a parasitic concentration greater than 75% of the trypomastigote forms was 
considered.
Cells. RAW 264.7 macrophages (ATCC number TIB-71) and 3T3 fibroblast (ATCC CRL-1658) cell lines were 
cultured in DMEM (Cultilab, Campinas, SP, Brazil) supplemented with 10% (v/v) fetal serum bovine (FBS) (Cul-
tilab, Campinas, SP, Brazil) and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin). The cells were 
incubated at 37 C in a humidified atmosphere with 5%  CO2. For maintenance of the cells, the culture medium 
was changed every three days, and the cells were further subcultured at 80% confluence using a cell scraper 
(RAW cells) or trypsin/EDTA (3T3 cells).
Determination of DETC antiparasitic activity against different strains and forms of Trypano-
soma cruzi. The different strains and forms of T. cruzi, mentioned above, were used in this study. The para-
sites were diluted in a concentration of 1.0 ×  107 parasites/mL and then 200 µL kept in 96-well plates together 
with different concentrations of sodium diethyldithiocarbamate (DETC) solved in LIT medium, ranged from 
4.44 to 444.00 µM. The antiparasitic activity of DETC was determined through the viability of the parasites after 
a treatment period of 24 and 48 h. Benznidazole was used as a positive control of antiparasitic activity against T. 
cruzi, in different concentrations that ranged from 3.84 to 500.00 µM. This range was selected due to an exist-
ing variability response against the different strains of T. cruzi and to determinate the  IC50 of benznidazole to 
compare with DETC.
Parasite viability was determined by the resazurin (Sigma Aldrich, Laramie, WY, USA) reduction assay at a 
concentration of 1 mM and subsequently measured by spectrophotometer (Epoch, BioTek Instruments, Win-
ooski, VT, USA), at 570 nm and 600 nm  wavelengths51. The antiparasitic activity of DETC was expressed as % 
of resazurin reduction = 100 – [(Atest570 – (Atest600*Ro))/(Acontrol570—(Acontrol600*Ro)] × 100, in which 
Atest corresponds to the absorbance of the experimental group, and Acontrol corresponds to the absorbance of 
the negative control, 570 and 600 are the wavelengths that correspond to 570 nm and 600 nm, Ro represents the 
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index of correction between the medium and resazurin, that allows to analyse if DETC interfere in the resazurin 
activity used during the test. It was observed that DETC does not interfere in the resazurin activity. Based on the 
percentage of reduction in resazurin, the  IC50 of the compounds were calculated, representing the concentration 
of the drug needed to reduce the viability of a parasitic population by 50%.
The viability of the parasites was also determined by microscopy in a clear camera through direct counting in a 
Neubauer camera. In this assay, parasites with some movement were considered viable. Cell viability results were 
compared between the two methodologies. In some conditions, when the DETC concentration produced 100% 
of parasite mortality, they were removed from the culture medium and later centrifuged (2,000 rpm, 10 min, 4 
C) to remove the drug. Afterwards, the parasites received a new-LIT medium, supplemented with 10% (v/v) FBS 
and 5% of antibiotic streptomycin/penicillin (100 UI/mL). After 7 days, the culture was analysed by conventional 
optical microscopy. The absence of live parasites confirms 100% mortality.
Evaluation of the membrane structure alteration in Trypanosoma cruzi submitted to DETC by 
scanning electron microscopy. To evaluate possible morphological changes in the membrane of different 
strains of T. cruzi caused by DETC, the parasite membrane structure was analysed by scanning electron micros-
copy after treatment with DETC, according to a protocol established by Amorim-Carmo et al.,  201952. Briefly, 
the epimastigote forms of the different strains of T. cruzi (1.0 ×  107 parasites/mL), in the same cultivation condi-
tions described previously in topic 2.2, were treated with DETC (44.40 µM, 111.00 µM and 222.00 µM), also in 
identical conditions described previously. After 24 h, the parasites were centrifuged for 10 min at 2000 rpm (4 
C) and washed twice in a saline solution (0.9% NaCl) pH 7.4. The parasites were then fixed in solution of 2.5% 
glutaraldehyde in PBS (v/v) for 4 h. After this step, the parasites were dehydrated, being exposed to different 
ethanol concentrations. First, to dehydrate the parasite, ethanol at 25% was added and left to stand for 10 min, 
followed by washes in a saline solution (0.9% NaCl) pH 7.4 for 10 min at 1500 rpm room temperature. The same 
operation was repeated for 50%, 80%, and 100% ethanol concentrations to dehydrate the parasite for next steps. 
Then, the parasites were resuspended in absolute ethanol, discarded on silicon plates and placed to dry at room 
temperature. Finally, once dry, the parasites were placed on stubs and subjected to metallization with gold using 
the sputtering (Bal-Tec SCD-005 Sputter Coater, Schalksmühle, NWR, GER) in an argon atmosphere for 30 s 
with a current of 30 mA, and then analysed by a scanning electron microscopy under a FEG microscope (Model 
augira, Brand Carl Zeiss, Oberkochen, WB, GER). In addition, an X-ray spectroscopy for energy dispersion 
(SED) was performed, in order to validate the results in the SEM. This technique allows the visualisation of the 
elements present in the samples, the structure and components of parasites, and allows identification of the pres-
ence or absence of residues and impurities.
3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide) tetrazolium (MTT) reduction 
assay on cell viability submitted to DETC. The ability of RAW 264.7 macrophages and fibroblast 3T3 
to reduce MTT was evaluated according to the previously described method of  Mosmann53. Initially, the cells 
were seeded in 96-well plates at a density of 5 × 103/well and kept at culture condition for 12 h. Then, the culture 
medium was replaced by another medium containing DETC in the different concentrations (from 4.444 to 
2.222 µM). After 24 h, the culture medium was replaced with 100 μL of MTT (1 mg/mL dissolved in DMEM). 
Then, the cells were incubated for 4 h at 37 C. Subsequently, the culture supernatant was discarded, and the crys-
tals of formazan were solubilized in ethanol, 100 μL/well. Absorbance was measured with an Epoch microplate 
spectrophotometer (Biotek Instruments Inc., Winooski, VT, USA) at 570 nm. Cell viability was calculated in 
relation to the negative control using the formula: % viability = (Atest/AControl) × 100, in which Atest corre-
sponds to the absorbance of the experimental group, and Acontrol corresponds to the absorbance of the negative 
control. Based on % MTT reduction,  IC50, that represents the drug concentration necessary to reduce by fifty per 
cent the cell population, was calculate. In order to analyse a possible chemical incompatibility between DETC 
and MTT, wells were analysed containing only the DMEM, DETC and MTT culture medium. It was observed 
that DETC does not interact chemically with MTT.
Determination of selective index of DETC. To assess the predilection of DETC between the par-
asite and cell, the Selective Index (SI) was used. This Index represents the preference of drug calculated by: 
SI =  IC50parasite/IC50cell; in which  IC50 parasite represents the drug concentration to reduce by fifty per cent the 
parasite population in vitro and  IC50 cell represents the drug concentration to reduce by fifty per cent the in vitro 
cell population.
Evaluation of death mechanism in Trypanosoma cruzi caused by DETC. Annexin V/PI (pro-
pidium iodide) was used to evaluate the DETC death mechanism at T. cruzi. Briefly, the epimastigotes and 
trypomastigotes forms of the different strains of T. cruzi, in the same culture conditions described previously in 
topic 2.2, were exposed to DETC (4.44 µM, 44.40 µM or 444.00 µM) for 24 h. Then, the parasites were centri-
fuged (2000 rpm for 5 min, 4 C), rinsed with PBS 1 × pH 7.4 (Phosphate-Saline Buffer), and suspended in 300 µL 
bond buffer 1×. Then, 5 µL of Annexin V-FITC (fluorescein isothiocyanate) was added to the system, let reacting 
for 10 min. Then, the parasites were centrifuged (2000 rpm for 5 min, 4 C) and resuspended again in 200 µL Bind 
Buffer and 10 µL of PI. Actinomycin D (20.0 mM) was used as positive control. All these steps are described in 
the protocol proposed by the manufacturer (Annexin V-FITC Apoptosis Detection Kit, Invitrogen, Carlsbad, 
CA, USA). After 10 min, the fluorescence intensity was determined using a flow cytometer (FACSCanto II, BD 
Biosciences, Eugene, OR, USA) with FACSDiva software, version 6.1.2 (Becton Dickson, Franklin Lakes, NJ, 
USA). For the analysis, we counted 10,000 events for each strain and evolutionary form of T. cruzi. A solution 
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of 100% DMSO was used as positive control using the same protocol of Annexin V/PI stain of DETC. The solu-
tion was added in the wells and the parasite was exposed for 24 h. Conditions were the same used in topic 2.2.
Evaluation of mitochondrial damage in Trypanosoma cruzi by DETC. In order to analyse the 
mitochondrial damage induced in different strains and forms of T. cruzi by DETC, the mitochondrial potential 
marker, rhodamine-123 (Invitrogen, Carlsbad, CA, USA) was used, following the manufacturer’s recommen-
dations. Briefly, the different strains and forms of T. cruzi were treated with different concentrations of DETC 
(44.40 µM; 111.00 µM; or 222.00 µM) for 24 h in the same conditions described previously. After treatment, the 
parasites were centrifuged at 2000 rpm for 6 min at 4 C and rinsed with PBS pH 7.4. Then, the parasites were 
suspended and 200 µL of PBS and 0.5 µL of rhodamine-123 (5 mg/mL) were added, as described by Sulsen 
et al.,  201654. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP; 100.0 μM) was used as positive control. After 
30 min, the parasites were rinsed twice in PBS and analysed by flow cytometry at wavelengths of 488 and 633 nm. 
Finally, the fluorescence intensity was determined by flow cytometer (FACSCanto II, BD Biosciences, Eugene, 
OR, USA) with FACSDiva software, version 6.1.2 (Becton Dickson, Franklin Lakes, NJ, USA). The parasites 
mitochondrial activity was calculated according to the formula: reduction of probe attachment (%) = (fluores-
cence intensity of the parasites treated with DETC)/(fluorescence intensity of negative control) * 100. A total of 
10,000 events were analysed for each strain and form of T. cruzi.
Evaluation of reactive oxygen species production in Trypanosoma cruzi by DETC. In order 
to analyse the reactive oxygen species production in different strains of T. cruzi after treatment with DETC, 
the marker 2´,7´-dichlorofluorescin diacetate (Sigma, Saint Louis, MO, USA) was  used55. Briefly, the differ-
ent strains and forms of T. cruzi were treated with different concentrations of DETC (44.40 µM; 111.00 µM; or 
222.00 µM) for 24 h in the same conditions described previously. After treatment, the parasites were centrifuged 
at 2000 rpm for 6 min at 4 C and washed with PBS pH 7.4. Afterward, these parasites were loaded with 10 µM of 
2´,7´-dichlorofluorescin diacetate and maintained in dark for 45 min. The endogenous ROS hydrogen peroxide 
 (H2O2) was used as a positive control 0.5 mM. The reactive oxygen species production was measured by increase 
of fluorescence caused by conversion of probe, and read at equipment  GloMax® Discover Microplate Read model 
GM 3000 (Fitchburg, Madison, USA) at λex = 490–530.
Statistical analysis of the data. All experiments were carried out in triplicate and independently. The 
results are presented in the form of arithmetic mean ± standard deviation. Data were submitted to the Shapiro–
Wilk normality test. Parametric data were analysed using the ANOVA test associated with the Tukey-T post-test 
(for more of 2 groups), t-student test (for 2 groups), and Pearson correlation. Tests were performed using the 
software GraphPad Prism v. 7.0 (2016) and P.A.S.T v. 2.17 (2012) (https:// palaeo- elect ronica. org/ 2001_1/ past/ 
issue1_ 01. htm).
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